Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses
Description
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS-CoV-2 pandemic. Nirmatrelvir-an orally available inhibitor of the 3-chymotrypsin-like cysteine protease-has been shown to reduce the risk of progression to
